Tuvusertib (M1774) in Participants With Metastatic or Locally Advanced Unresectable Solid Tumors (DDRiver Solid Tumors 301)

Metastatic or Locally Advanced Unresectable Solid Tumors Clinical Trial

Official title:
An Open-label, Multicenter Trial of the Safety, Tolerability, and Pharmacokinetic/Pharmacodynamic Profile of Tuvusertib (M1774) in Participants With Metastatic or Locally Advanced Unresectable Solid Tumors (DDRiver Solid Tumors 301)

Status Active, not recruiting

Clinical Trial Summary

This is an open-label, Phase I, first-in-human (FIH) multicenter, clinical study conducted in multiple parts to establish the safety, tolerability and pharmacokinetic/pharmacodynamic (PK/PD) profile (with and without food) and early signs of efficacy of Tuvuseritib (M1774) as monotherapy and in combination with the poly (ADP-ribose) polymerase (PARP) inhibitor niraparib.

Clinical Trial Description

n/a

Study Design

Related Conditions & MeSH terms

Metastatic or Locally Advanced Unresectable Solid Tumors
Neoplasms

Clinical Trial Details

NCT number	NCT04170153
Study type	Interventional
Source	EMD Serono
Contact
Status	Active, not recruiting
Phase	Phase 1
Start date	December 20, 2019
Completion date	January 30, 2025

View Details

See also
Status	Clinical Trial	Phase
Terminated	`NCT03306420` - First-in-Human Study of MS201408-0005A as Single Agent and in Combinations	Phase 1
Terminated	`NCT05198349` - First in Human Study of M1069 in Advanced Solid Tumors	Phase 1
Recruiting	`NCT05396833` - Study of Tuvusertib (M1774) in Combination With DNA Damage Response Inhibitor or Immune Checkpoint Inhibitor (DDRiver Solid Tumors 320)	Phase 1